Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 307

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 307
---
 leverage our team’s collective operational experience and disciplined investment approach to identify opportunities to unlock and maximize value. These criteria are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors, and criteria that our management may deem relevant. In the BLAC M&A Committee’s review, OSR Holdings’ pipeline of assets primarily consists of biologics, including DNA cancer vaccines and engineered (“design -augmented”) chimeric protein. Certain assets include technology/research platforms geared toward target engagement which increased therapeutic index, which can be seen as an innovative and more precise approach to medicine. In this respect, the OSR Holdings franchise and portfolio fits the related investment criteria, especially the “Focus on Innovation” and “Attractive Risk -AdjustedEquity Returns.” Each OSR Holdings asset is geared toward a specific unmet need and technology approach. The OSR Holdings team is a cross -functionalteam with a core expertise and ecosystem adapted to the current type and stage of assets in its portfolio. Consequently, the BLAC M&A Committee concluded that it is fair to consider OSR Holdings as a target business that corresponds to the Investment Criteria set forth in the IPO Prospectus of BLAC. As noted above, BLAC identified various criteria and guidelines to use in evaluating acquisition opportunities, but also noted that it may decide to enter into an initial business combination with a target business that did not meet all of some of these criteria and guidelines. The criteria and guidelines, among others, are highlighted by that BLAC would choose to enter into a business combination with a company that is well situated to act as a standalone public company, that has a novel platform with catalysts to drive shareholder value and for which there is the opportunity for further value 182 creation as a public company, through organic and inorganic growth. The BLAC M&A Committee considered each of these factors in its evaluation of OSR Holdings and determined that OSR Holdings was an attractive business combination target taking these criteria and guidelines into consideration. In addition to the material findings uncovered during diligence, the BLAC M&A Committee considered a number of factors pertaining to the Business Combination as generally supporting the decision to enter into the Business Combination Agreement and the transactions contemplated thereby, including but not limited to, the following material factors: • Strong management team The consolidated management team from the holding company to each subsidiary consists of experienced professionals coming from scientific, entrepreneurial, capital market and regulatory backgrounds who, as